

2015-2019 Japanese Tumor Marker Testing Market: Supplier Shares, Country Forecasts, Innovative Technologies, Competitive Strategies

https://marketpublishers.com/r/298BD9F3695EN.html

Date: June 2015

Pages: 590

Price: US\$ 6,080.00 (Single User License)

ID: 298BD9F3695EN

Abstracts

Complete report \$7,600. DataPack (test volumes, sales forecasts, supplier shares) \$4,300. 2015-2019 Japanese Tumor Marker Testing Market is a newstrategic analysis of the major business opportunities emerging in the cancer diagnostics market during the nextfive years. The report examines trends in the Japanese cancer diagnostics markets; reviews current and emerging tests; analyzes potential applications of various diagnostic technologies; forecasts sales of major tumor markers and market segment; profiles leading market players and potential entrants; and suggests alternative business expansion strategies for suppliers. Rationale The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion. Business Opportunities and Strategic Recommendations- Specific new product development opportunities with potentially significant market appeal during the next five years. - Design criteria for new products. - Alternative market penetration strategies. - Potential market entry barriers and risks. Cancer Diagnostic Tests Over 200 current and emerging assays including: ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27. 29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA, Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG, Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar, Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid



Hormone, Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein, Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin, Tissue Polypeptide Antigen, and others. Market Segmentation Analysis- Sales and market shares of major suppliers, by individual cancer diagnostic test. - Five-year test volume and sales forecasts for major cancer diagnostic tests by market segment, including:- Hospitals- Commercial/Private Laboratories- Comprehensive market segmentation analysis, including reviewof the market dynamics, structure, size, growth and major suppliers. - Cancer statistics, etiology and recent developments. Current and Emerging Products- Review of over 200 current and emerging cancer diagnostic tests, including: - Biochemical Markers-Oncogenes- Growth Factors- Hormones- Colony Stimulating Factors- Lymphokines-Immunohistochemical Stains, and others. - Analysis of major immunoassay analyzers used forcancer diagnostic testing, including their operating characteristics, features and selling prices. Technology Review- Assessment of monoclonal antibodies, immunoassays, DNAprobes, biochips/microarrays, chromosome analysis, IT, artificial intelligence, flow cytometry, biosensors, and other technologies and their potential applications for cancer diagnostic testing. - Review of competing/complementing technologies, includingCT, MRI, NMR, PET and photonics spectroscopy. - Extensive listings of over 500 companies, universities and research centers developing new cancer diagnostic tests and detection technologies. Competitive Assessments- Strategic assessments ofmajor suppliers and start-up firms developing innovative technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D. Contains 590 pages and 95 tables



Contents

I. INTRODUCTION

II. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES

- A. Reagent Kits and Test Systems/Panels
- B. Instrumentation
- C. Computers, Software and Automation
- D. Auxiliary Products

III. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS

IV. ALTERNATIVE MARKET PENETRATION STRATEGIES

- A. Internal Development
- B. Collaborative Arrangements
- C. University Contracts
- D. Distribution Strategies
 - 1. Marketing Approaches
 - 2. Product Complexity
 - 3. Customer Preference
 - 4. Established Suppliers
 - 5. Emerging Suppliers
 - 6. Major Types of Distributors
 - 7. Market Segmentation Factor

V. POTENTIAL MARKET ENTRY BARRIERS AND RISKS

- A. Market Maturity
- B. Cost Containment
- C. Competition
- D. Technological Edge and Limitations
- E. Patent Protection
- F. Regulatory Constraints
- G. Decentralized Testing Market Challenges

VI. WORLDWIDE MARKET AND TECHNOLOGY OVERVIEW



- A. Cancer Statistics and Etiology
 - 1. Breast Cancer
 - 2. Lung Cancer
 - 3. Colon and Rectum Cancer
 - 4. Prostate Cancer
 - 5. Stomach Cancer
 - 6. Leukemia
 - 7. Lymphoma
 - 8. Oral Cancer
 - 9. Skin Cancer
 - 10. Uterine Cancer
 - 11. Ovarian Cancer
 - 12. Bladder Cancer
- B. Major Current And Emerging Cancer Diagnostic Tests
 - 1. Introduction
 - 2. Tumor Marker Classification
 - 3. ACTH
 - 4. Alpha-Fetoprotein (AFP)
 - 5. Beta-2 Microglobulin
 - 6. CA 15-3/27.29
 - 7. CA 19-9
 - 8. CA-125
 - 9. Calcitonin
 - 10. Carcinoembrionic Antigen (CEA)
 - 11. Estrogen and Progesterone Receptors
 - 12. Ferritin
 - 13. Gastrin
 - 14. Human Chorionic Gonadotropin (HCG)
 - 15. Insulin
 - 16. NSE
 - 17. Occult Blood
 - 18. PAP Smear/HPV
 - 19. Prostatic Acid Phosphatase (PAP)
 - 20. Prostate-Specific Antigen (PSA)
 - 21. Squamous Cell Carcinoma Antigen (SCC)
 - 22. T and B Lymphocytes
 - 23. TdT
 - 24. Thyroglobulin
 - 25. Tissue Polypeptide Antigen (TPA)



26. Biochemical Tumor Markers **ADA B-Protein PNP** 5'-Nucleotidase 27. Oncogenes Abl/abl-bcr AIB1 BCL-2 BRCA1 **CD44** C-fos C-myb C-myc CYP-17 Erb-B HPC1 N-myc P40 P51 P53 PIK3CA PTI-1 Ras Reg Sis Src 28. Polypeptide Growth Factors Basic Fibroblast Growth Factor Beta-TGF Cachectin (TNT) Calmodulin **ECFR** Nerve Growth Factor (NGF) Epidermal Growth Factor (EGF) Ornithine Decarboxylase

Transforming Growth Factor-Alpha

Transferrin

29. Ectopic Hormones



30. Colony Stimulating Factors

31. Lymphokines

Alpha-Interferon

B Cell Growth Factors

B Cell Growth Factor (BCGF)

B Cell Growth Factor (BCGF)

Interleukin-1 (IL-1)

Macrophage Activating Factor

32. Immunohistochemical Stains

33. Emerging Tumor Markers

N-Acetylglucosamine

Actin

Alpha-Actin

Antineuronal Antibodies

7B2

B72.3

Bax

BCD-F9

BLCA-4

Blood Group Antigens A,B,H

CA

CA 72-4/TAG-72

CA

CA-242

CA-549

CAM

CAR-3

Cathepsin-D

Chromogranin A and B

Cluster 1 Antigen

Cluster-5/5A Antigen

CTA

CU18

DR-70

DU-PAN-2

Endometrial Bleeding Associated Factor

Endostatin

Epithelial Membrane Antigen

Feulgen Hydrolysis



Fibronectin

FSH

(1->3)-L-fucosyltransferase

Gastrin-Releasing Peptide (GRP)

GDCFP-15

Glucagon

Glycoamines

H23

Her-2

Human Carcinoma Antigen

HPA

HSP27

Intermediate Filaments

Cytokeratins/CK18/Cyfra 21-1

Desmin

Gliofibrillary Acid Protein

Neurofilaments

Vimentin

KΑ

Kinases

KP16D3

LAI

Leukocyte Common Antigen

Lewis Antigens

Lysophosphatidic Acid (LPA)

Ma 695/Ma

MABDF3

MAG

ME1

Minactivin

MN/CA9

MSA

Mucin Cancer Antigen (MCA)

Multiple Tumor Suppressor

Myosin

NEA-130

NMP22

OA-519

Opiod Peptides



P-glycoprotein

Pancreatic Oncofetal Antigen (POA)

Placental Lactogen

PR92

Proliferative Index, Ki-67

Px

RB Inactivation/Deletion

Ret

SCCL

Selectin

Sialic Acid

Sialyl SSEA-1/SLX

SN10

Somatostatin

TA-90

TABA

Tachykinin

TAG

TPS

Troponin

Tubulin

VCAM

VEGF

Villen

- C. Instrumentation Review And Market Needs
- D. Current and Emerging Technologies
 - 1. Monoclonal and Polyclonal Antibodies
 - 2. Immunoassays
 - a. Technological Principle
 - b. Radioimmunoassay (RIA)
 - c. Enzyme Immunoassays (EIA)

Overview

ELISA

Immunofiltration

Particle-Membrane Capture Immunoassay

Enzyme Amplification

- d. Fluorescent Immunoassays
- e. Luminescence

Chemiluminescence



Bioluminescence

- f. Latex Agglutination
- g. Immunoprecipitation
- h. Affinity Chromatographu
- e. Liposome Flow-Injection Immunoassay
- 3. Molecular Diagnostics
 - a. Technology Overview
 - b. Amplification Methods
- 4. Chromosome Analysis
 - a. Chronic Myelogenous Leukemia (CML)
 - b. Acute Myeloid Leukemia (AML)
 - c. Acute Lymphoblastic Leukemia (ALL)
 - d. Malignant Lymphomas Lymphoid Malignancies
 - e. Chronic Lymphocytic Leukemia (CLL)
 - f. Solid Cancers
- g. Chromosomal Translocation and Oncogenes
- 5. Artificial Intelligence
- 6. Flow Cytometry
- 7. Two Dimensional Gel Electrophoresis (2-DGE)
- 8. Biosensors
- 9. Competing/Complementing Technologies
 - a. CT
 - b. MRI
 - c. NMR
 - d. PET
 - e. Photonics Spectroscopy
- E. Personal Testing

VII. JAPAN

- A. Executive Summary
- B. Business Environment
- C. Market Structure
- D. Market Size, Growth and Major Suppliers' Sales And Market Shares

VIII. COMPETITIVE PROFILES

Abbott

AdnaGen



Agilent Technologies

Applied Gene Technologies

Arca/Nuvelo

Beckman Coulter/Danaher

Becton Dickinson

Biomedical Diagnostics

bioMerieux

Bio-Rad

CellSearch

Cepheid

Correlogic Systems/Vermillion

Decode

Diadexus

Diagnocure

Diasorin

Eiken Chemical

Epigenomics

Enterix

Enzo Biochem

Exact Sciences

Fujirebio/Innogenetics

Guided Therapeutics

Hologic/Gen-Probe

Kreatech

Kyowa Medex

Life Technologies

Mackay Life Sciences

Myriad Genetics

Nanogen Elitech

OncoLab

Ortho-Clinical Diagnostics

Panacea Pharmaceuticals

Polartechnics

Polymedco

PreMD

Qiagen/Ipsogen

Quest Diagnostics

Radient Pharmaceuticals

Roche



Scienion

Sequenom

Siemens Healthcare

Takara Bio

Targeted Diagnostics & Therapeutics

Tosoh

Veridex

Wako Pure Chemicals

Wallac/PE

Zila

IX. APPENDIXES: APPENDIX I: MAJOR UNIVERSITIES AND RESEARCH CENTERS DEVELOPING CANCER DIAGNOSTIC TECHNOLOGY AND APPLICATIONS

Appendix II: Assumed Currency Exchange Rates



List Of Tables

LIST OF TABLES

Tumor Marker Classification

Major Companies Developing or Marketing ACTH Tests

Major Companies Developing or Marketing AFP Tests

Major Companies Developing or Marketing Beta-2 Microglobulin Tests

Major Companies Developing or Marketing CA 15-3/27.29 Tests

Major Companies Developing or Marketing CA 19-9 Tests

Major Companies Developing or Marketing CA 125 Tests

Major Companies Developing or Marketing Calcitonin Tests

Major Companies Developing or Marketing CEA Tests

Major Companies Developing or Marketing Estrogen Receptor Tests

Major Companies Developing or Marketing Progesterone Receptor Tests

Major Companies Developing or Marketing Ferritin Tests

Major Companies Developing or Marketing Gastrin Tests

Major Companies Developing or Marketing HCG Tests

Major Companies Developing or Marketing Insulin Tests

Major Companies Developing or Marketing NSE Tests

Major Companies Developing or Marketing Occult Blood Tests

Major Companies Developing or Marketing PAP Smear/HPV Tests

Major Companies Developing or Marketing PAP Tests

Major Companies Developing or Marketing PSA Tests

Major Companies Developing or Marketing Lymphocyte Subclassification Tests

Biochemical Markers Potential Applications In Cancer Diagnosis

Oncogenes Potential Applications In Cancer Diagnosis

Major Companies Developing or Marketing Oncogene Tests

Growth Factors Potential Applications In Cancer Diagnosis

Colony Stimulating Factors Potential Applications in Cancer Diagnosis

Lymphokines Potential Applications In Cancer Diagnosis

Immunohistochemical Stains Potential Applications in Cancer Diagnosis

Executive Summary Table: Japan, Total Tumor Marker Test Volume and Sales

Forecast by Market Segment

Japan, Estimated Cancer Death Rates Per 100,000 Population

Japan, Laboratories Performing Tumor Marker Tests by Market Segment

Japan, Hospital Laboratories Performing Tumor Marker Tests by Bed Size

Japan, Commercial/Private Laboratories Performing Tumor Marker Tests By Annual Test Volume



Japan, Total Tumor Marker Testing Volume Forecast by Market Segment
Japan, All Market Segments Major Tumor Marker Test Volume Forecast
Japan, Hospital Laboratories Major Tumor Marker Test Volume Forecast by Test
Japan, Commercial/Private Laboratories Major Tumor Marker Test Volume Forecast
Japan, Total Tumor Marker Sales Forecast by Market Segment
Japan, All Market Segments Major Tumor Marker Sales Forecast by Test
Japan, Hospital Laboratories Major Tumor Marker Sales Forecast by Test
Japan, Commercial/Private Laboratories Major Tumor Marker Sales Forecast by Test
Japan, ACTH Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, Beta-2 Microglobulin Test Volume and Diagnostics Sales Forecast by Market
Segment

Japan, CA 15-3/27.29 Test Volume and Diagnostics Sales Forecast by Market Segment Japan, CA 19-9 Test Volume and Diagnostics Sales Forecast by Market Segment Japan, CA-125 Test Volume and Diagnostics Sales Forecast by Market Segment Japan, Calcitonin Test Volume and Diagnostics Sales Forecast by Market Segment Japan, Cathepsin Test Volume and Diagnostics Sales Forecast by Market Segment Japan, CEA Test Volume and Diagnostics Sales Forecast by Market Segment Japan, Chromogranin Test Volume and Diagnostics Sales Forecast by Market Segment Japan, Colon-Specific Antigen Test Volume And Diagnostics Sales Forecast by Market Segment Segment

Japan, Cytokeratins Test Volume and Diagnostics Sales Forecast by Market Segment Japan, Estrogen Receptor Test Volume and Diagnostics Sales Forecast by Market Segment

Japan, Ferritin Test Volume and Diagnostics Sales Forecast by Market Segment Japan, Gastrin Test Volume and Diagnostics Sales Forecast by Market Segment Japan, HCG Test Volume and Diagnostics Sales Forecast by Market Segment Japan, Insulin Test Volume and Diagnostics Sales Forecast by Market Segment Japan, Interferons Test Volume and Diagnostics Sales Forecast by Market Segment Japan, Interleukins Test Volume and Diagnostics Sales Forecast by Market Segment Japan, Lymphocyte Subtyping Test Volume and Diagnostics Sales Forecast by Market Segment Segment

Japan, NSE Test Volume and Diagnostics Sales Forecast by Market Segment Japan, Nucleolar Test Volume and Diagnostics Sales Forecast by Market Segment Japan, Occult Blood Test Volume and Diagnostics Sales Forecast by Market Segment Japan, Oncogenes Test Volume and Diagnostics Sales Forecast by Market Segment Japan, Pancreatic Oncofetal Antigen Test Volume and Diagnostics Sales Forecast by Market Segment

Japan, PAP Smear Test Volume and Diagnostics Sales Forecast by Market Segment



Japan, Parathyroid Hormone Test Volume and Diagnostics Sales Forecast by Market Segment

Japan, Progesterone Receptor Test Volume and Diagnostics Sales Forecast by Market Segment

Japan, PAP Test Volume and Diagnostics Sales Forecast by Market Segment Japan, PSA Test Volume and Diagnostics Sales Forecast by Market Segment Japan, S-100 Protein Test Volume and Diagnostics Sales Forecast by Market Segment Japan, Serotonin Test Volume and Diagnostics Sales Forecast by Market Segment Japan, Sialic Acid Test Volume and Diagnostics Sales Forecast by Market Segment Japan, Squamous Cell Carcinoma Antigen Test Volume and Diagnostics Sales Forecast by Market Segment

Japan, TDT Test Volume and Diagnostics Sales Forecast by Market Segment Japan, Thymidine Kinase Test Volume and Diagnostics Sales Forecast by Market Segment

Japan, Thyroglobulin Test Volume and Diagnostics Sales Forecast by Market Segment

Japan, TPA, Test Volume and Diagnostics Sales Forecast by Market Segment

Japan, Total Tumor Marker Sales by Major Suppliers

Japan, AFP Testing Market Diagnostics Sales by Major Supplier

Japan, CA 15-3/27.29 Testing Market Diagnostics Sales by Major Supplier

Japan, CA 19-9 Testing Market Diagnostics Sales by Major Supplier

Japan, CA 125 Testing Market Diagnostics Sales by Major Supplier

Japan, Calcitonin Testing Market Diagnostics Sales by Major Supplier

Japan, PAP Testing Market Diagnostics Sales by Major Supplier

Japan, PSA Testing Market Diagnostics Sales by Major Supplier



I would like to order

Product name: 2015-2019 Japanese Tumor Marker Testing Market: Supplier Shares, Country Forecasts,

Innovative Technologies, Competitive Strategies

Product link: https://marketpublishers.com/r/298BD9F3695EN.html

Price: US\$ 6,080.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/298BD9F3695EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970



